Prognostic role of NLR in urinary cancers: a meta-analysis.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 24642859.
- Also identified by DOI 10.1371/journal.pone.0092079 and PMC identifier 3958449.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Recently, many studies explored the role of inflammation parameters such as neutrophil-to-lymphocyte ratio (NLR) in the prognosis of urinary cancers, but the results were not consistent. We carried out a meta-analysis of published studies to assess the prognostic value of NLR in patients with urinary cancers. Hazard ratio (OR) with 95% confidence interval (CI) was used to assess the association of NLR and OS and RFS/CSS. The pooled results showed that high NLR was a poor predictor for OS with HR of 1.81 (95%CI: 1.48-2.21; Pheterogeneity = 0.005) and RFS/CSS (HR = 2.07, 95% CI: 1.65-2.6; Pheterogeneity = 0.849). Subgroup analyses revealed that high NLR yielded a worse OS in RCC (HR = 1.9, 95%CI: 1.47-2.45; Pheterogeneity = 0.003) and a poor RFS/CSS in RCC (HR = 1.83, 95%CI: 1.35-2.48; Pheterogeneity = 0.709), bladder cancer (HR = 2.2, 95%CI: 1.27-3.8; Pheterogeneity = 0.447) and urothelial carcinoma (HR = 2.58, 95%CI: 1.66-4.01; Pheterogeneity = 0.784). Our results showed that NLR could act as a significant biomarker in the prognosis of urinary cancers.
Medical subject headings
- Lymphocytes
- Neutrophils
- Urologic Neoplasms